Paige
Paige develops AI foundation models and clinical-grade applications for cancer pathology diagnostics and biomarker discovery, serving hospital systems and pharmaceutical clients with FDA-authorized diagnostic suites and the Alba co-pilot.
- Company typePrivate
- Founded2017
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Paige does
Paige is a New York-based AI company that builds software for cancer pathology, founded in 2017 (per company history) by Thomas Fuchs of Memorial Sloan Kettering and operating as Paige.AI, Inc. Its core technology is a series of proprietary pathology foundation models — Virchow (632M parameters), Virchow2 and Virchow2G (1.8B parameters each), and the multimodal PRISM/PRISM2 — trained on more than 3 million digitized pathology slides from over 800 laboratories across 45 countries and 225,000+ patients, with access to a broader pool of ~25 million slides. On top of these models Paige delivers tissue-specific diagnostic suites (Paige Prostate Suite, Breast Suite, GI Suite, PanCancer Suite), the FDA-cleared FullFocus whole-slide image viewer, the OmniScreen biomarker prescreening tool that simulates 1,600 cancer biomarkers, and Paige Alba, a multi-modal AI co-pilot with voice and text commands for pathology workflows.
Paige sells primarily through enterprise SaaS subscription licensing with annual, quote-based pricing, distributed via direct enterprise sales teams and channel partners including Sectra, Epredia, and OptraSCAN. The customer base spans hospital systems and academic medical centers (e.g., Ohio State Wexner, University Medical Center Utrecht, NHS Wales, Burjeel Holdings, Grupo Oncoclinicas, University of Florida Jacksonville) and pharmaceutical/life sciences organizations using Paige's AI for biomarker discovery, companion diagnostics, and clinical trial design. The company holds the first FDA De Novo authorization for AI in digital pathology (2021), FDA Breakthrough Device Designation, multiple 510(k) clearances, and CE-IVD/UKCA marks for products marketed in Europe and the UK.
As of August 2025, Paige was acquired by Tempus AI for $81.25 million (predominantly in Tempus common stock plus assumption of Paige's Microsoft Azure cloud agreement), ending its status as an independent entity and positioning Paige's foundation models, dataset, and team inside Tempus's larger precision-medicine platform.
Paige firmographics
Firmographics- Name
- Paige
- Legal name
- Paige.AI, Inc.
- Website
- https://paige.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Paige develops AI foundation models and clinical-grade applications for cancer pathology diagnostics and biomarker discovery, serving hospital systems and pharmaceutical clients with FDA-authorized diagnostic suites and the Alba co-pilot.
- Ownership category
- akta.pro rank
Paige industry classification
Industry- Product category
- Digital Pathology AI Software
- NAICS
- Software Publishers (513210), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Paige is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Paige business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- SaaS Subscription Licensing: Software-as-a-service subscription licensing model providing access to AI-powered pathology diagnostic tools on a recurring basis.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription pricing (not publicly disclosed) |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Paige product offering
Product offeringCore offering
Paige develops AI-powered clinical software for cancer pathology, including tissue-specific diagnostic suites (Prostate, Breast, GI), a pan-cancer detection suite, the FDA-cleared FullFocus whole-slide image viewer, the biomarker screening tool OmniScreen, and the Paige Alba AI co-pilot. The portfolio is built on proprietary foundation models (Virchow, Virchow2, Virchow2G, PRISM2) trained on more than 3 million digitized pathology slides and is sold as enterprise subscriptions to clinical laboratories and licensed to pharmaceutical and life-sciences partners.
Product overview
Paige offers a comprehensive platform of clinical AI applications for cancer diagnostics built on proprietary foundation models and a vast digital pathology dataset of over 25 million accessible pathology slides from 350,000 patients across 45 countries. The portfolio includes diagnostic AI suites for specific tissue types (Prostate Suite, Breast Suite, GI Suite) and pan-cancer detection (PanCancer Suite), alongside the AI co-pilot Alba, the FDA-cleared FullFocus whole-slide image viewer, and OmniScreen for biomarker screening. The platform also provides foundation models (Virchow, Virchow2, Virchow2G, PRISM2) available for licensing and custom AI development services for pharmaceutical and life sciences partners. Paige's technology enables cancer detection, grading, biomarker prediction, and precision medicine workflows across clinical practice and drug development.
Differentiator
Problem solved
Functional benefit
Brands
- Paige Prostate Suite: AI applications for detecting and diagnosing prostate cancer on H&E-stained whole-slide images
- Paige Breast Suite
- Paige GI Suite
- Paige PanCancer Suite
- FullFocus
- Paige Alba
- Virchow
- Virchow2
- Virchow2G
- PRISM
- PRISM2
- OmniScreen
- Paige Colon MSI
Products and services
- Paige Prostate Suite Comprehensive AI applications that aid detection and diagnosis of prostate cancer on H&E-stained whole-slide images of prostate needle biopsies, including cancer detection, Gleason pattern grading, tumor quantification, and perineural invasion identification, for clinical pathology laboratories.
- Paige Breast Suite AI applications that support pathologists in identifying and classifying breast cancer on H&E-stained whole-slide images from breast biopsy and excision specimens, including lymph node metastasis detection and mitotic counting.
- Paige GI Suite Portfolio of AI-powered applications supporting pathologists in detecting and classifying benign and malignant conditions across the entire gastrointestinal tract, built on Paige's latest foundation model technology.
- Paige PanCancer Suite AI applications developed using the Virchow foundation model and cumulatively trained on over 1.5 million slides to help pathologists identify cancer across multiple tissue types including rare cancers and metastatic deposits.
- Paige Alba Proprietary multi-modal AI co-pilot that integrates Paige's diagnostic and foundation model technologies with voice and text commands to streamline pathologists' cancer detection and diagnosis workflows and provide real-time clinical insights.
- FullFocus FDA-cleared, CE-IVDR marked, and UKCA marked whole-slide image viewer that enables physicians to unlock digital pathology and AI's full potential, with diagnostic and collaboration tools, AI visualizations, and multi-scanner compatibility.
- OmniScreen AI tool that simultaneously screens 505 genes for comprehensive cancer diagnosis and personalized treatment selection by simulating a panel of 1,600 clinically significant cancer biomarkers from H&E-stained images, enabling rapid biomarker identification for therapeutic targeting and clinical trial design.
- Virchow Foundation Model Family (Virchow, Virchow2, Virchow2G, Virchow2G-Mini) Pathology foundation models with up to 1.8 billion parameters trained on 3+ million digitized slides across 800+ labs and 45 countries, providing general-purpose computational pathology capabilities for cancer detection, biomarker prediction, and custom AI development by Paige and its partners.
- PRISM2 Slide-level multimodal foundation model trained on over 2.3 million whole-slide images paired with clinical reports and integrated with Microsoft Phi-3, enabling diagnostic, biomarker prediction, and multi-modal patient outcome modeling through connection of visual patterns with clinical language.
- AI Technology & Services Comprehensive services offering Paige foundation models and AI modules for third-party partners, custom AI development, prognostic or predictive application development, regulatory strategy, and commercialization services for life sciences and pharmaceutical organizations.
Quantifiable outcome
- First FDA authorization for AI-assisted cancer detection in digital pathology
- +3 more outcomes
Companies that use Paige
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
Paige technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability9 records
Feature5 records
Paige partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, flagship and minor.
- MicrosoftcoreCollaboration on AI foundation models for cancer diagnosis, leveraging Microsoft's cloud and AI infrastructure to advance digital pathology capabilities.
- Leica BiosystemscoreExpanded partnership for digital pathology workflows, integrating Paige AI with Leica's pathology instruments and systems.
- Breast International Group (BIG)coreStrategic partnership for AI-driven breast cancer research, combining BIG's clinical research expertise with Paige's AI capabilities.
- Burjeel HoldingsflagshipPartnership to deploy FDA-approved AI across MENA region, bringing AI-powered cancer diagnostics to healthcare facilities in the Middle East and North Africa.
- SectracoreDistribution agreement for Paige's AI applications through Sectra's digital pathology platform, expanding market reach in Europe and globally.
- EprediacoreGlobal commercial distribution agreement enabling Epredia to distribute Paige AI solutions alongside their pathology products worldwide.
- NHS Wales (Betsi Cadwaladr University Health Board)flagshipPilot project for PanCancer Detect, implementing AI-powered cancer screening in NHS Wales healthcare facilities.
- University Medical Center UtrechtcoreResearch partnership for CONFIDENT-P study, collaborating on clinical validation of AI for cancer diagnostics.
- University of YorkminorAI safety program partnership focused on responsible development and deployment of AI in pathology.
- University of OxfordminorResearch collaboration on patient perspectives regarding AI use in cancer diagnostics.
- Ohio State Wexner Medical CenterflagshipCollaboration on AI tools development and clinical implementation for pathology diagnostics.
- University of Florida College of Medicine - JacksonvillecoreAdoption and implementation of Paige AI for pathology diagnostics in academic medical center setting.
- OptraSCANminorPartnership to streamline digital pathology adoption through OptraSCAN's scanning and imaging solutions.
Scale indicators8 records
Recent moves6 records
Expansion highlights8 records
Paige competitors and assessment
Company assessmentDirect peers
- Owkin: Owkin applies AI to pathology and multimodal patient data for drug discovery and diagnostics. It targets overlapping pharma and clinical customers with foundation-model approaches similar to Paige's Virchow roadmap.
- PathAI: PathAI is a leading AI pathology company developing diagnostic and biomarker products on its AISight image management platform. It is the most direct competitor to Paige, offering overlapping cancer detection AI and integrating Paige's own products alongside its own algorithms.
- Ibex Medical Analytics: Ibex develops AI-powered cancer diagnostics for pathology, with FDA-cleared products for breast and prostate cancer detection. It competes head-to-head with Paige's Prostate and Breast Suites across enterprise pathology customers.
- Proscia: Proscia offers a digital pathology platform with AI applications for cancer diagnosis and biomarker quantification. It competes with Paige's FullFocus viewer and diagnostic AI suites across research and clinical labs.
- Aiforia: Aiforia provides AI image analysis solutions for pathology, including cancer detection and grading. Paige has an active integration partnership with Aiforia, and the two compete in AI-assisted clinical diagnostics.
- Deep Bio: Deep Bio develops AI for prostate cancer pathology and is integrated into PathAI's AISight alongside Paige's prostate products. It is a focused direct competitor in Paige's flagship prostate suite category.
- Mindpeak: Mindpeak builds AI tools for cancer diagnosis in pathology and has a joint integration partnership with Paige. Both companies offer complementary AI applications across the same clinical pathology customer base.
- Visiopharm: Visiopharm provides AI-driven image analysis for digital pathology, including cancer diagnostics and research applications. Its products are integrated into PathAI AISight alongside Paige's, positioning it as a direct peer in the same deployment ecosystem.
Broad incumbents
- Philips (Digital Pathology): Philips is a major incumbent in digital pathology scanners and workflow software. Its Ultrafast Scanner is part of Paige's FullFocus compatibility ecosystem, and its broader healthcare AI portfolio overlaps with Paige's clinical ambitions.
- Roche (Digital Pathology): Roche's digital pathology division offers whole-slide imaging, image management, and AI workflow tools as part of its broader diagnostics portfolio. It competes with Paige on enterprise pathology platforms while also partnering across the broader oncology ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Paige social profiles
Digital presencePaige compliance and trust
Trust signalCompliance7 records
Paige financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paige leadership team
Management profileNumber of profiles
Profiles6 records
Paige funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paige M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paige
What does Paige do?
Paige develops AI-powered clinical software for cancer pathology, including tissue-specific diagnostic suites (Prostate, Breast, GI), a pan-cancer detection suite, the FDA-cleared FullFocus whole-slide image viewer, the biomarker screening tool OmniScreen, and the Paige Alba AI co-pilot. The portfolio is built on proprietary foundation models (Virchow, Virchow2, Virchow2G, PRISM2) trained on more than 3 million digitized pathology slides and is sold as enterprise subscriptions to clinical laboratories and licensed to pharmaceutical and life-sciences partners.
Is Paige a public or private company?
Paige is a private company. It is classified as corporate owned and is currently acquired.
When was Paige founded?
Paige was founded in 2017. It employs 51 to 100 people.
Where is Paige based?
Paige is headquartered in New York, United States, in the North America region.
How does Paige make money?
One revenue line is on record: saaS Subscription Licensing.
Who are Paige's main competitors?
Direct peers on record are Owkin, PathAI, Ibex Medical Analytics, Proscia, Aiforia, Deep Bio, Mindpeak and Visiopharm. Broad incumbents are Philips (Digital Pathology) and Roche (Digital Pathology).
Does Paige have an API?
No public API is recorded for Paige.
What industry is Paige in?
Paige's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.